The expression of hDlg as a biomarker of the outcome in malignant fibrous histiocytomas

  • Authors:
    • Rui Niimi
    • Akihiko Matsumine
    • Takahiro Iino
    • Tetsuya Murata
    • Ken Shintani
    • Shigeto Nakazora
    • Tomoki Nakamura
    • Yudai Uehara
    • Katsuyuki Kusuzaki
    • Tetsu Akiyama
    • Atsumasa Uchida
  • View Affiliations

  • Published online on: March 1, 2010     https://doi.org/10.3892/or_00000678
  • Pages: 631-638
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The human homologue of Drosophila disc large tumor suppressor protein (hDlg) is one of the proteins known to act cooperatively in regulating cell polarity and proliferation, suggesting an important connection between epithelial organization and cellular growth control. An abnormal expression of hDlg has been reported in several cancer types. However, the expression of hDlg in soft-tissue sarcomas has not yet been reported. We examined the expression of hDlg immunohistochemically in 46 specimens of malignant fibrous histiocytoma (MFH). The expression of hDlg was negative in 19 specimens, weak in 4, moderate in 16, and strong in 7. The patients with a weak or negative expression of hDlg had a significantly shorter metastasis-free survival rate and disease-free survival rate in comparison with those with a strong or moderate expression in both univariate analysis (p=0.0287 and 0.0237, respectively; log-rank test) and multivariate analysis (p=0.0087 and 0.0126, respectively; Cox proportional hazards regression model). Moreover, the patients with a weak or negative expression of hDlg had a significantly shorter overall survival rate in comparison with those with a strong or moderate expression in a univariate analysis (p=0.0214; log-rank test). This is the first report to demonstrate that a reduced expression of hDlg protein is an independent negative prognostic factor for MFH.

Related Articles

Journal Cover

March 2010
Volume 23 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Niimi R, Matsumine A, Iino T, Murata T, Shintani K, Nakazora S, Nakamura T, Uehara Y, Kusuzaki K, Akiyama T, Akiyama T, et al: The expression of hDlg as a biomarker of the outcome in malignant fibrous histiocytomas. Oncol Rep 23: 631-638, 2010
APA
Niimi, R., Matsumine, A., Iino, T., Murata, T., Shintani, K., Nakazora, S. ... Uchida, A. (2010). The expression of hDlg as a biomarker of the outcome in malignant fibrous histiocytomas. Oncology Reports, 23, 631-638. https://doi.org/10.3892/or_00000678
MLA
Niimi, R., Matsumine, A., Iino, T., Murata, T., Shintani, K., Nakazora, S., Nakamura, T., Uehara, Y., Kusuzaki, K., Akiyama, T., Uchida, A."The expression of hDlg as a biomarker of the outcome in malignant fibrous histiocytomas". Oncology Reports 23.3 (2010): 631-638.
Chicago
Niimi, R., Matsumine, A., Iino, T., Murata, T., Shintani, K., Nakazora, S., Nakamura, T., Uehara, Y., Kusuzaki, K., Akiyama, T., Uchida, A."The expression of hDlg as a biomarker of the outcome in malignant fibrous histiocytomas". Oncology Reports 23, no. 3 (2010): 631-638. https://doi.org/10.3892/or_00000678